The FDA approved long-acting anticholinergic was indicated for the maintenance treatment of bronchospasm coupled with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.
When administered two times a day using the preloaded, multidose Pressair inhaler, Tudorza inhibits muscarinic M3 receptor in the airway smooth muscle and produces bronchodilation.
Forest Laboratories has commercialization rights for aclidinium in the US while both Forest and Almirall will jointly promote the product in Canada.
Almirall holds the rights of the product in remaining parts of the world.